TANG KEVIN purchased $12K of BOLD (indirect holdings)

TANG KEVIN purchased 4,863 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.44 across 3 trades over 2026-07-17 to 2026-07-21.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jul 21, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

A newly filed insider open-market purchase by a 10% owner can modestly support sentiment, but the disclosed value is small and indirect, limiting trading impact.

02

Market read

Traders may note the insider buy as a minor positive signal, but it is unlikely to be a standalone catalyst.

03

What to watch

No 10b5-1 plan is cited, but the filing does not explain intent, timing constraints, or whether the buyer’s broader position is changing materially beyond the disclosed share count.

Relevance 3/10Novelty 4/10Timing: Filed on 2026-07-21 for purchases executed 2026-07-17 to 2026-07-21.

Background

The article is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD).

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

SEC Form 4 shows 10% owner Tang Kevin bought 4,863 shares of Boundless Bio at $2.44/share via an open-market purchase (indirect) filed July 21.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 is primary-source and newly disclosed today, but the transaction value (~$11.9k) is small relative to typical market caps, and the ownership is indirect with no 10b5-1 plan stated.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Indirect holdings and small size can reflect routine rebalancing or non-informational motives, so the buy may not signal improved fundamentals.

Key entities

  • Boundless Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tang Kevin

    10% owner reporting an indirect open-market purchase of BOLD shares.

  • SEC Form 4

    Primary-source disclosure filed 2026-07-21 covering trades from 2026-07-17 to 2026-07-21.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.